Literature DB >> 1301210

High level expression of human apolipoprotein A-I in transgenic rats raises total serum high density lipoprotein cholesterol and lowers rat apolipoprotein A-I.

M E Swanson1, T E Hughes, I S Denny, D S France, J R Paterniti, C Tapparelli, P Gfeller, K Bürki.   

Abstract

To examine the consequences of increased apolipoprotein A-I production on cholesterol and lipoprotein metabolism, we have produced two lines of transgenic rats; one expressing moderate and one very high levels of human apolipoprotein A-I. The rats were produced by microinjection of a 13 kbp DNA fragment containing the human apolipoprotein A-I gene plus 10 kbp of its 5' flanking sequence and 1 kbp of its 3' flanking sequence. Both lines of transgenic rats express human apolipoprotein A-I mRNA in liver and human apolipoprotein A-I in plasma. Sera from these rats contain significantly higher levels of total apolipoprotein A-I, high density lipoprotein cholesterol and phospholipid than sera from non-transgenic littermates. Transgenic rats expressing high levels of human apolipoprotein A-I have reduced levels of serum rat apolipoprotein A-I suggesting a mechanism exists to down-regulate apolipoprotein A-I production. These transgenic rats provide a unique animal model to examine the effects of increased apolipoprotein A-I production on lipid and lipoprotein metabolism.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1301210     DOI: 10.1007/bf02528779

Source DB:  PubMed          Journal:  Transgenic Res        ISSN: 0962-8819            Impact factor:   2.788


  20 in total

1.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

2.  Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease.

Authors:  G J Miller; N E Miller
Journal:  Lancet       Date:  1975-01-04       Impact factor: 79.321

3.  Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice.

Authors:  Y Ito; N Azrolan; A O'Connell; A Walsh; J L Breslow
Journal:  Science       Date:  1990-08-17       Impact factor: 47.728

4.  Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses.

Authors:  E M Rubin; B Y Ishida; S M Clift; R M Krauss
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-15       Impact factor: 11.205

5.  Nonimmunochemical quantitation of mammalian apolipoprotein A-I in whole serum or plasma by nonreducing gel electrophoresis.

Authors:  D S France; T E Hughes; R Miserendino; J A Spirito; J Babiak; J B Eskesen; C Tapparelli; J R Paterniti
Journal:  J Lipid Res       Date:  1989-12       Impact factor: 5.922

6.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study.

Authors:  T Gordon; W P Castelli; M C Hjortland; W B Kannel; T R Dawber
Journal:  Am J Med       Date:  1977-05       Impact factor: 4.965

7.  Identification of an enhancer-like element in the 5' flanking region of the rat apolipoprotein A-I gene.

Authors:  Y S Chao; X H Ding; P H Dai; T J Wu; T C Pan; Q L Hao; T T Yamin
Journal:  Nucleic Acids Res       Date:  1988-07-25       Impact factor: 16.971

8.  Tissue-specific expression of apolipoprotein A-I (ApoA-I) is regulated by the 5'-flanking region of the human ApoA-I gene.

Authors:  K Higuchi; S W Law; J M Hoeg; U K Schumacher; N Meglin; H B Brewer
Journal:  J Biol Chem       Date:  1988-12-05       Impact factor: 5.157

9.  Different cis-acting DNA elements control expression of the human apolipoprotein AI gene in different cell types.

Authors:  K N Sastry; U Seedorf; S K Karathanasis
Journal:  Mol Cell Biol       Date:  1988-02       Impact factor: 4.272

10.  High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.

Authors:  D J Gordon; J L Probstfield; R J Garrison; J D Neaton; W P Castelli; J D Knoke; D R Jacobs; S Bangdiwala; H A Tyroler
Journal:  Circulation       Date:  1989-01       Impact factor: 29.690

View more
  8 in total

Review 1.  Transgenic animals as models for human disease--report of an EC Study Group.

Authors:  R Lathe; J J Mullins
Journal:  Transgenic Res       Date:  1993-09       Impact factor: 2.788

Review 2.  Transgenesis in the rat and larger mammals.

Authors:  L J Mullins; J J Mullins
Journal:  J Clin Invest       Date:  1996-04-01       Impact factor: 14.808

Review 3.  Transgenic modifications of the rat genome.

Authors:  Laurent Tesson; Jean Cozzi; Séverine Ménoret; Séverine Rémy; Claire Usal; Alexandre Fraichard; Ignacio Anegon
Journal:  Transgenic Res       Date:  2005-10       Impact factor: 2.788

Review 4.  Transgenesis in rats: technical aspects and models.

Authors:  B Charreau; L Tesson; J P Soulillou; C Pourcel; I Anegon
Journal:  Transgenic Res       Date:  1996-07       Impact factor: 2.788

5.  Ectopic expression of tethered human follicle-stimulating hormone (hFSH) gene in transgenic mice.

Authors:  Myoung Ok Kim; Sung Hyun Kim; Sang Ryeul Lee; Mi Jung Shin; Kwan Sik Min; Dong Beom Lee; Sung Won Lee; Kil Soo Kim; Sun Jung Kim; Zae Young Ryoo
Journal:  Transgenic Res       Date:  2006-11-11       Impact factor: 2.788

6.  Advances in transgenic rat production.

Authors:  Wanda E Filipiak; Thomas L Saunders
Journal:  Transgenic Res       Date:  2006-09-29       Impact factor: 2.788

7.  Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice.

Authors:  C Pászty; N Maeda; J Verstuyft; E M Rubin
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

Review 8.  Transgenic mouse models of lipoprotein metabolism and atherosclerosis.

Authors:  J L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.